Yes, Spruce Biosciences, Inc. (Nasdaq: SPRB) executed a corporate stock split in the form of a 1-for-75 reverse stock split, which took effect in August 2025. The primary objective behind implementing this reverse stock split was to consolidate the company's outstanding common shares and elevate the per-share market price in order to regain and maintain compliance with the Nasdaq Stock Market's minimum bid price requirement of $1.00 per share for continued public listing on the Nasdaq Capital Market. Under the terms of the 1-for-75 reverse split, every 75 shares of issued and outstanding common stock held by shareholders were automatically combined and converted into one single post-split common share, without changing any shareholder's proportional equity percentage or the fundamental underlying valuation of the enterprise. Additionally, the reverse split proportionally reduced the total authorized and outstanding share count while adjusting the exercise prices and share amounts associated with outstanding stock options, restricted stock units, and warrants.